



Policy Regarding Shareholder Communications with the Board of Directors

(as adopted on February 22, 2006)

The Board of Directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) takes seriously the fiduciary responsibilities it owes to the Company’s stockholders. The Board believes that establishing a means by which stockholders have the ability to communicate effectively with members of Board will assist the Board in satisfying these responsibilities. In that regard, the Board has adopted the following means for stockholders and others to communicate with the Company’s Board of Directors:

- If the stockholder or other person has a concern regarding the Company’s financial statements, accounting practices or internal controls, the concern should be submitted in writing to the Chairperson of the Company’s Audit Committee in care of the Company’s Vice President, Finance at the Company’s headquarters address.
- If the concern relates to the Company’s governance practices, business ethics or corporate conduct, the concern should be submitted in writing to the Chairman of the Board in care of the Corporation’s Treasurer at the Company’s headquarters address.
- If a stockholder or other person is unsure as to which category the concern relates, the stockholder may communicate it to any one of the independent directors in care of the Company’s Vice President, Finance at the Company’s headquarters address.

All stockholder communications will promptly be forwarded to the applicable director(s).